(19)
(11) EP 4 572 775 A2

(12)

(88) Date of publication A3:
25.04.2024

(43) Date of publication:
25.06.2025 Bulletin 2025/26

(21) Application number: 23855611.2

(22) Date of filing: 15.08.2023
(51) International Patent Classification (IPC): 
A61K 35/17(2025.01)
A61P 37/06(2006.01)
A61P 35/00(2006.01)
C12N 5/0783(2010.01)
C12N 5/10(2006.01)
A61K 35/15(2025.01)
(52) Cooperative Patent Classification (CPC):
A61K 35/17; A61P 37/06; A61K 40/15; A61K 40/22; A61K 40/32; A61K 40/50
(86) International application number:
PCT/US2023/072223
(87) International publication number:
WO 2024/040061 (22.02.2024 Gazette 2024/08)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 16.08.2022 US 202263398408 P

(71) Applicant: The Regents of University of California
Oakland, CA 94607-5200 (US)

(72) Inventors:
  • YANG, Lili
    Los Angeles, California 90024 (US)
  • LI, Yan-Ruide
    North Hills, California 91343 (US)

(74) Representative: Murgitroyd & Company 
165-169 Scotland Street
Glasgow G5 8PL
Glasgow G5 8PL (GB)

   


(54) ALLEVIATING GRAFT VERSUS HOST DISEASE USING ENGINEERED INKT CELLS